Kari Youman, MD
Psychiatry · Tulsa, OKNPI 1851439756
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 392 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 15.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,230 and has fallen 98.8% since, to $15 in 2024.
Across 392 payments — averaging $13.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$819
- Otsuka America Pharmaceutical, Inc.$767
- Lundbeck LLC$706
- Alkermes, Inc.$487
- Takeda Pharmaceuticals U.S.A., Inc.$430
- Johnson & Johnson$415
- plus $2K from 19 others
What the payments were for
- Food & beverage$5,24699%
- Education$421%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 95 | $819 |
| Otsuka America Pharmaceutical, Inc. | 57 | $767 |
| Lundbeck LLC | 60 | $706 |
| Alkermes, Inc. | 25 | $487 |
| Takeda Pharmaceuticals U.S.A., Inc. | 33 | $430 |
| Johnson & Johnson | 17 | $415 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 18 | $312 |
| Jazz Pharmaceuticals Inc. | 12 | $188 |
| Avanir Pharmaceuticals, Inc. | 12 | $169 |
| Axsome Therapeutics, Inc. | 5 | $138 |
| Sunovion Pharmaceuticals Inc. | 11 | $126 |
| Shire North American Group Inc | 8 | $114 |
| Supernus Pharmaceuticals, Inc. | 5 | $95 |
| Eisai Inc. | 6 | $89 |
| Teva Pharmaceuticals USA, Inc. | 6 | $82 |
| Almatica Pharma LLC | 4 | $74 |
| Corium, LLC | 3 | $59 |
| Adlon Therapeutics L.p. | 4 | $55 |
| Vanda Pharmaceuticals Inc. | 3 | $44 |
| Noven Therapeutics, LLC | 2 | $32 |
| Orexo US, Inc. | 2 | $32 |
| Biogen | 1 | $15 |
| Indivior Inc. | 1 | $15 |
| Bausch Health US, LLC | 1 | $14 |
| Livanova USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPRAVATO$124
How this compares
$5,288 in reported general payments places this provider in the 85th percentile of 328 psychiatry providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 11 | $94,770 |
| VraylarCariprazine Hcl | 28 | $56,472 |
| RexultiBrexpiprazole | 18 | $27,927 |
| TrintellixVortioxetine Hydrobromide | 37 | $21,702 |
| NuedextaDextromethorphan Hbr/Quinidine | 11 | $16,447 |
| AuvelityDextromethorphan Hbr/Bupropion | 14 | $13,203 |
| VyvanseLisdexamfetamine Dimesylate | 27 | $10,123 |
| Aripiprazole | 78 | $8,408 |
| Duloxetine Hcl | 130 | $5,889 |
| Ziprasidone Hcl | 59 | $5,616 |
| Vilazodone Hcl | 61 | $5,554 |
| Clozapine | 91 | $4,928 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 61 | $4,834 |
| Clonazepam | 293 | $4,287 |
| Quetiapine Fumarate | 255 | $3,923 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $819 | $56,47228 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $430 | $31,82564 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $767 | $27,92718 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $169 | $16,44711 claims |
| Axsome Therapeutics, Inc.Auvelity | $138 | $13,20314 claims |
| Almatica Pharma LLCSertraline Hcl | $74 | $1,720129 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 328 psychiatry providers in Oklahoma.
Other psychiatry in Tulsa
- Sarah LandTulsa$287K
- Bradley McClureTulsa$15K
- Katrina CraderTulsa$15K
- Jeffrey CatesTulsa$11K
- Kaitlin CoresTulsa$10K
- Charles van TuylTulsa$9K
- Michael DubriwnyTulsa$8K
- Martin PaulusTulsa$7K
- Joe SpeerTulsa$7K
- Stevan LahrTulsa$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.